MedImpact Holdings Inc., the largest independent pharmacy benefit and health solutions company, announced that it will offer access to an unbranded biosimilar ustekinumab-aekn at a substantially lower cost than the reference product, Stelara (ustekinumab). Distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., the biosimilar will be available for direct purchase through MedImpact’s preferred partner, Birdi, Inc., to any licensed specialty pharmacy.

Arpit Patel, senior vice president of trade relations and supply chain at MedImpact, said the company’s unbranded strategy was designed to bypass unnecessary supply chain costs. “We designed our unbranded strategy to bypass these costs to deliver far greater value to pharmacies and payers, and a more affordable treatment option for patients,” he stated.

With specialty drug costs rising and many pharmacies closing, MedImpact’s strategy introduces a new sourcing model that provides pharmacies with access to lower prices while giving payers more flexibility and control over healthcare expenses. Importantly, this approach will extend beyond MedImpact’s own clients, offering broader industry-wide benefits.

As part of an industry shift away from rebates and towards transparency, the initiative will enable payers and members to access lower prices directly at the point of sale. Leveraging an FDA-designated interchangeable biosimilar purchased from Anda, supported by Teva’s expertise in biosimilars, the strategy is expected to encourage greater physician prescribing, patient acceptance, and significant cost savings.

Patel added, “MedImpact’s specialty strategy is deeply rooted in the principle that pharmacies, members, and payers should not have to compromise access for affordability, and this strategy delivers on that promise. The unbranded ustekinumab-aekn is the first of many products we will provide to expand access, drive affordability, and transform the specialty drug market.”

The unbranded ustekinumab-aekn biosimilar will be available for purchase beginning January 1, 2026.

MedImpact Holdings Inc. continues to build solutions that make healthcare more predictable, personal, and affordable.